The Following Were Members of the ______ Study Group: M

The authors wish to acknowledge Mary S. Richardson, Pharm.D. for editorial coordination and assistance, Gillian Smith for statistical analysis, and Jenny Christal, Ph.D. for study implementation and management.

The authors wish to thank the patients and the investigators who participated in the trial.

The following were members of the Rosiglitazone in AD Study Group: M. Rainer, Vienna, Austria; J. Marksteiner, Univ. Klinik Innsbruck, Psychiatrie, Austria; M. Haushofer, SMZ Ost – Donauspital, Psychiatrische Abteilung, Vienna, Austria; H. Schubert, Psychiatrisches Krankenhaus, Hall i.T, Austria; M. Schmitz, Vienna, Austria; L. Traykov, University Hospital Alexandrovska, Bulgaria; P. Stamenova, University Hospital Queen Joana, Bulgaria; I. Milanov, University Hospital St. Naum, Bulgaria; N. Deleva, University Hospital Sveta Marina, Bulgaria; V. Demarin, Klinicka Bolnica Sestre Milosrdnice, Croatia; V. Folnegovic Smalc, Psihjatrijska Bolnica Vrapce, Croatia; N. Henigsberg, Poliklinika Neuron, Croatia; I. Zedkova, FN Olomouc, Czech Republic; J. Drahozal, Mestska Nemocnice Litomerice, Czech Republic; E. Topinkova, VFN Praha, Czech Republic; J. Hort, FN Motol, Czech Republic ; U. Linnamagi, Tartu University Clinics, Estonia; P. Jaanson, Jaanson & Laane Outpatients Clinic, Estonia; K. Aadamsoo, North Estonian Regional Hospital, Estonia; T. Toomsoo, East-Tallinn Central Hospital, Estonia; K. Gross-Paju, West-Tallinn Central Hospital, Estonia; B. Bergtholdt, Emovis GMBH, Berlin, Germany; J. Bohringer, Bielefeld, Germany; H.G. Damman, Hamburg, Germany; R. Felgentreff, Haldensleben, Germany; K.O. Sigel, Bielefeld, Germany; A. Hause, Achim, Germany; R. Lehmann, Klinische Forschung Berlin-Buch, Berlin, Germany; G. Roth, Ostfildern, Germany; J. Peltz, Hattingen, Germany; H. R. Schellenberg, Huttenberg, Germany; H. Klepel, Madgeburg, Germany; P. Laumen, Germany; H. Sommer, Köthen Germany; G. Schumann, Art Fur Neurologie Und Psychiatrie, Bochum, Germany; K. C. Steinwachs, Nürnberg, Germany; H. J. Gertz, AFL Arzneimittelforschung, Leipzig, Germany; S. Behrens, Berlin, Germany; X. Fitsioris, Hospital of Papageorgiou, Thessaloniki, Greece; D. Mitsikostas, naval Hospital of Athens, Athens, Greece; M. Tsolaki, General Hospital of Thessaloniki, Thessaloniki, Greece; A. Papadimitriou, Errikos Dynan Hospital, Athens, Greece; D. Vassilopoulos, Aigintio Hospital, Athens, Greece; C. Piperidou, General University Hospital of Alexandroupoli, Alexandroupoli, Greece; G. Bartko, Jahn Ference Delpeesti Korhaz, Budapest, Hungary; I. Degrell, Deoec, Debrecen, Hungary; Z. Janka, Szegedi Tudomanyegyetem, Budapest, Hungary; G. Ostorharics, Petz Aladar Megyei Korhaz, Budapest, Hungary; A. Szczudlik, Centrum Neurologii Klinicznej, Warsaw, Poland; Z. Cebulski, 103 Szpital Wojskowy, Warsaw, Poland; A. Araszkiewicz, Akademia Medyczna, Katowice, Poland; J. Laczkowski, Osrodek Lecznictwa Psychiatrycznego, Warsaw, Poland; H. Kwiecinski, Samodzielny Publiczny, Warsaw, Poland; Z. Stelmasiak, Samodzielny Publiczny, Warsaw, Poland; A. Guekht, Neurology & Neurosugery Dept. RGMU, Russian Federation; V. Kontsevoy, Scientific Center of Mental Health, Russian Federation; S. Gavrilova, Psychiatry Clinic #15, Russian Federation; N. Neznanov, Geriatric Center, Russian Federation; J. Pena, Centro Geriatrico, Barcelona, Spain; M. Aguilar, Mutua de Tarrasa, Barcelona, Spain; A. Frank, Hospital La Paz, Madrid, Spain; M. Boada, Fundacion Ace, Barcelona, Spain; R. Blesa, Hospital Santa Creu I Sant Pau, Barcelona, Spain; J. Olazaran, Hospital Gregorio Maranon, Madrid, Spain; A. Caminero, Hospital Nuestra Senora de Sonsoles, Avila, Spain; J. Alom, Hospital General University de Elche, Elche, Spain; N. Gilchrist, CGMM Research Trust, New Zealand; P. Wood, Waitemata Specialist Center, New Zealand